Ibex, Leading AI Cancer Diagnostics, Unveils Detection Platform
Ibex Medical Analytics, a leader in AI-powered cancer diagnostics, has launched a new cancer detection platform.
The Galen 3.0 uses improved AI algorithms to detect cancer in prostate, breast and gastric biopsies. The platform also calculates a Gleason score (the grading system used to determine the aggressiveness of prostate cancer), tumor size, and percentage for each cancer slide, potentially enabling pathologists to save review time and reduce subjectivity.
“With an estimated 1.9 million new cancer cases diagnosed in the United States alone this year, we are excited to bring Galen 3.0 to pathology labs worldwide, providing clinically validated, automated decision-support tools that help pathologists diagnose cancer more rapidly and more accurately to support the high demand,” said Issar Yazbin, Vice President of Product Management at Ibex.
Ibex’s Galen platform is the first and most widely deployed AI technology in pathology, and is used routinely in hospitals, laboratories, and health systems worldwide. It supports pathologists with diagnostic tasks during the review of breast, prostate, and gastric biopsies and helps improve the quality of cancer diagnosis, reduce turnaround time, boost productivity, and improve user experience for pathologists.
In June 2021, the platform received a Breakthrough Device Designation from the United States Food and Drug Administration (FDA). The FDA’s Breakthrough Device Designation is granted to technologies that have the potential to provide more effective treatment or diagnosis of life-threatening diseases.
Ibex says the designation will enable close collaboration with, and expedited review by the FDA, and provides formal acknowledgment of the Galen platform’s potential benefit as well as the robustness of Ibex’s clinical program.
Ibex was founded in 2016 and is headquartered in Tel Aviv.